VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, with emphasis on major depressive disorder, neuropathic pain, Parkinson's disease LID, social anxiety disorder and suicidal ideation. VistaGen's AV-101, an oral NMDAR GlyB antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators with the potential to treat major depressive disorder faster and with fewer side effects than currently available FDA-approved antidepressants which, if effective, often take many weeks to months to achieve therapeutic benefits and are associated with side effects and safety concerns. With at-home convenience of an oral therapy, AV-101 has the potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. The FDA has granted Fast Track designation to AV-101 for development as an adjunctive treatment for major depressive disorder and as a non-opioid treatment of chronic neuropathic pain. VistaGen's PH10 and PH94B were developed from proprietary compounds called pherines. With intranasal administration, PH10 and PH94B act locally on peripheral nasal chemosensory receptors that trigger rapid activation of neural impulses in areas of the brain associated with depression (PH10) social anxiety disorder (PH94B). This mechanism of pharmacological action, the rapid onset of efficacy, and the excellent safety and tolerability profile demonstrated in clinical trials to date make PH10 and PH94B, respectively, excellent product candidates for chronic treatment of patients with depression and for on-demand (PRN) treatment of social anxiety disorder. Source
No articles found.
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, ...
Kaleido Biosciences is a clinical-stage healthc...
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiri...
MediciNova, Inc. is a publicly-traded biopharma...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...
Exicure, Inc. is a clinical stage biotechnology...
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
Join the National Investor Network and get the latest information with your interests in mind.